|Watchlist for Stem Cell Stock with Pending News|
|Friday, 26 February 2010 11:16|
The US National Institutes of Health (NIH) is proposing to extend the human embryonic stem cell (human ES cell) lines eligible for federal funding to include those from earlier-stage embryos than currently allowed.
From a scientific and ethical point of view there’s “no reason” to exclude lines derived earlier in embryonic development according to Lana Skirboll, who directs the NIH’s Office of Science Policy.
Skirboll says the issue came to the agency’s attention after Advanced Cell Technology Inc. (ACTC.OB), based in Worcester, Massachusetts, recently submitted for NIH approval five lines derived from blastomeres — single cells removed from morulas (which are embryos a few days old that have not yet become blastocysts).
This news, has set the stage for an upcoming development that could affect one or more of ACTC's stem cell programs as soon as next Wednesday (or sooner). Credible sources tell us the company may be making an announcement that could affect share price in a positive manner, so we wanted our subscribers to put this stock on your watchlists.
Related Story: ACTC likes new "tweaked" stem cell policy
Disclosure: Long ACTC